Objectives:

To describe the development and implementation of an omalizumab optimisation protocol in chronic spontaneous urticaria, showing reallife data.

Methods:

A retrospective descriptive study of patients with chronic spontaneous urticaria included in the omalizumab optimisation programme between 01/10/2020-01/06/2021 was conducted. Effectiveness was assessed by Urticaria Activity Score over 7 days (UAS7), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 months. Responders (UAS7£15) and non-responders (UAS7>15), as well as patients with good disease control (UAS7£6) and complete response (UAS7=0) were estimated. Savings from optimisation by dose reduction or discontinuation due to clinical improvement were calculated.

Results:

Forty-seven patients were included. Omalizumab was optimised in 29 patients (61.7%): 1 (2.1%) patient only presented dose reduction, 11 (23.4%) only treatment discontinuation and 17 (36.2%) had both interventions. Most effectiveness assessments presented between 70-90% of responders. Only the effectiveness valoration presented a lower proportion of responders (66.7%) at 12 months. The total economic savings associated with optimisation were 286,150.1 : 172,747.7 through treatment discontinuations and 113,402.4 through dose reductions.

Conclusions:

The optimisation protocol for omalizumab in chronic spontaneous urticaria provided high efficiency, maintaining an adequate effectiveness.

        · resumen en Español     · texto en Español     · Español ( pdf )